Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29324250
DOI
10.1016/j.bioorg.2017.12.034
PII: S0045-2068(17)30764-2
Knihovny.cz E-resources
- Keywords
- 1,3,5-Triazine, Benzene sulfonamides, Carbonic anhydrase, Enzyme inhibition, Isoform selectivity,
- MeSH
- Amino Alcohols chemistry pharmacology MeSH
- Antigens, Neoplasm metabolism MeSH
- Carbonic Anhydrase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Carbonic Anhydrase I antagonists & inhibitors metabolism MeSH
- Carbonic Anhydrase II antagonists & inhibitors metabolism MeSH
- Carbonic Anhydrase IX antagonists & inhibitors metabolism MeSH
- Humans MeSH
- Molecular Structure MeSH
- Piperazine chemistry pharmacology MeSH
- Sulfonamides chemistry pharmacology MeSH
- Triazines chemistry pharmacology MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Amino Alcohols MeSH
- Antigens, Neoplasm MeSH
- CA9 protein, human MeSH Browser
- Carbonic Anhydrase Inhibitors MeSH
- Carbonic Anhydrase I MeSH
- Carbonic Anhydrase II MeSH
- Carbonic Anhydrase IX MeSH
- Piperazine MeSH
- Sulfonamides MeSH
- Triazines MeSH
A new series of s-triazine derivatives incorporating sulfanilamide, homosulfanilamide, 4-aminoethyl-benzenesulfonamide and piperazine or aminoalcohol structural motifs is reported. Molecular docking was exploited to select compounds from virtual combinatorial library for synthesis and subsequent biological evaluation. The compounds were prepared by using step by step nucleophilic substitution of chlorine atoms from cyanuric chloride (2,4,6-trichloro-1,3,5-triazine). The compounds were tested as inhibitors of physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms. Specifically, against the cytosolic hCA I, II and tumor-associated hCA IX. These compounds show appreciable inhibition. hCA I was inhibited with KIs in the range of 8.5-2679.1 nM, hCA II with KIs in the range of 4.8-380.5 nM and hCA IX with KIs in the range of 0.4-307.7 nM. As other similar derivatives, some of the compounds showed good or excellent selectivity ratios for inhibiting hCA IX over hCA II, of 3.5-18.5. 4-[({4-Chloro-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)methyl] benzene sulfonamide demonstrated subnanomolar affinity for hCA IX (0.4 nM) and selectivity (18.50) over the cytosolic isoforms. This series of compounds may be of interest for the development of new, unconventional anticancer drugs targeting hypoxia-induced CA isoforms such as CA IX.
References provided by Crossref.org